enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. SGLT2 inhibitor - Wikipedia

   en.wikipedia.org/wiki/SGLT2_inhibitor

   Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors ...

3. Drugs like Ozempic may help lower 2nd stroke, heart attack risk

   www.aol.com/drugs-ozempic-may-help-lower...

   A new study says that type 2 diabetes medications GLP-1 agonists and SGLT2 inhibitors may help lower a stroke survivor’s risk of experiencing a subsequent stroke, heart attack, or death ...

4. Sodium/glucose cotransporter 2 - Wikipedia

   en.wikipedia.org/wiki/Sodium/glucose_cotransporter_2

   SGLT2 is a member of the sodium glucose cotransporter family, which are sodium-dependent glucose transport proteins. SGLT2 is the major cotransporter involved in glucose reabsorption in the kidney. [6] SGLT2 is located in the early proximal tubule, and is responsible for reabsorption of 80-90% of the glucose filtered by the kidney glomerulus. [7]

5. Canagliflozin - Wikipedia

   en.wikipedia.org/wiki/Canagliflozin

   Evidence shows that apart from positive effects on glycemic levels, canagliflozin also reduces the risk of heart attacks and heart failures. [14] SGLT2 inhibitors, including canagliflozin, reduce the likelihood of hospitalization for congestive heart failure or progression of renal disease in persons with diabetes mellitus type 2 and reduce the ...

6. 4 Ways to Prevent Muscle Loss on Ozempic & Other Weight ... - AOL

   www.aol.com/4-ways-prevent-muscle-loss-115800184...

   Other diabetes drugs, specifically sodium-glucose cotransporter 2 (SGLT2) inhibitors, can also lead to a reduction in lean mass. This includes canagliflozin (Invokana®) and dapagliflozin (Farxiga®).

7. Type 2 diabetes - Wikipedia

   en.wikipedia.org/wiki/Type_2_diabetes

   The American Diabetes Association and European Association for the Study of Diabetes recommend using a GLP-1 receptor agonist or SGLT2 inhibitor as the first-line treatment in patients who have or are at high risk for atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease.